Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03566199 · OUTCOME

Overall Survival Rate (OS) at 12 Months

MTX110 by Convection-Enhanced Delivery in Treating Participants With Newly-Diagnosed Diffuse Intrinsic Pontine Glioma · Source last updated 2022-02-25

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
percentage of participants
Interval / dispersion
95% Confidence Interval
Time frame
Up to 12 Months

What was measured

Overall survival is defined as the percentage of participants alive from time of diagnosis up to 12 months.

Analysis population: While individual participants were assigned to receive separate doses, participants are presented in one Arm/Group due to confidentiality concerns for this rare disease study

Groups in this outcome

Phase 1: Treatment (MTX110)

Participants receive panobinostat nanoparticle formulation MTX110 IT by CED infusion on day 1 or days 1 and 2 as determined by dose level. Courses repeat every 4-8 weeks for up to 24 months in the absence of disease progression or unacceptable toxicity. Panobinostat Nanoparticle Formulation MTX110: Given IT Convection-Enhanced Delivery (CED): Undergo CED

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Phase 1: Treatment (MTX110)7

Reported measurements

Source class 1
Values in percentage of participants · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Phase 1: Treatment (MTX110)85.7Not reported63.3100Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        63.3
        upper Limit
        100
        value
        85.7
denoms
  1. counts
    1. group Id
      OG000
      value
      7
    units
    Participants
description
Overall survival is defined as the percentage of participants alive from time of diagnosis up to 12 months.
dispersion Type
95% Confidence Interval
groups
  1. description
    Participants receive panobinostat nanoparticle formulation MTX110 IT by CED infusion on day 1 or days 1 and 2 as determined by dose level. Courses repeat every 4-8 weeks for up to 24 months in the absence of disease progression or unacceptable toxicity. Panobinostat Nanoparticle Formulation MTX110: Given IT Convection-Enhanced Delivery (CED): Undergo CED
    id
    OG000
    title
    Phase 1: Treatment (MTX110)
param Type
NUMBER
population Description
While individual participants were assigned to receive separate doses, participants are presented in one Arm/Group due to confidentiality concerns for this rare disease study
reporting Status
POSTED
time Frame
Up to 12 Months
title
Overall Survival Rate (OS) at 12 Months
type
SECONDARY
unit Of Measure
percentage of participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice